Truist Securities analyst Srikripa Devarakonda initiates coverage on Keros Therapeutics (NASDAQ: KROS) with a Buy rating and a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE